Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose

  • days left to enroll
  • participants needed
  • sponsor
    University Hospital, Caen
Updated on 25 January 2021
anti-angiogenic agents
blood transfusion
arteriovenous malformation
colorectal cancers


Epistaxis are present in over 90 % of patients with Rendu - Osler . They involve no significant difference 2 sexes. They often appear in childhood and adolescence and are present in three-quarters of patients at the age of 20 years. These epistaxis increasing in frequency and volume to the age of 60 in 2/3 of patients. Epistaxis are spontaneous , repetitive and recurring . They are highly variable in duration, intensity and frequency of occurrence . Some patients may have more than 40 monthly episodes with mean duration of 5 minutes of bleeding and chronic anemia and can sometimes acute anemia with transfusions need to be source. These epistaxis stigmatize patients and inevitably affect their quality of life and social skills . The various proposed ( cauterization , intra- mucosal injections, laser selective hmostatses , embolization or surgical dermoplasties ) allow for some short-term remissions . Bevacizumab is an antiangiogenic use in the treatment of colorectal cancers . It is also used in ophthalmology intravitreal to reduce vascular proliferation in glaucoma retinopathy and certain corneal neovascularization. In 2009, Prithviraj reported the use of bevacizumab injection to treat pulmonary arteriovenous malformations in a patient with Rendu

  • Osler . The result is doubly interesting including a saving action on epistaxis which decrease in frequency and duration. This communication prompted the authors to focus more on this medication. The product has been used in local submucosal injection intranasal laser was coupled with satisfactory results objectified by a decrease in the number of epistaxis , reducing blood transfusions and improved social lives. The use of local instillation bevacuzimab represents a way forward for the treatment of these epistaxis.

Condition Hereditary hemorrhagic telangiectasia
Treatment bevacuzimab spray
Clinical Study IdentifierNCT02157987
SponsorUniversity Hospital, Caen
Last Modified on25 January 2021


Yes No Not Sure

Inclusion Criteria

patients with Rendu-Osler-Weber disease
patients with iterative epistaxis (at least 10 per month)
patients without treatment for 3 months with usual techniques (for the epistaxis)
patients speaking french fluently
patients with written consents
affiliation to social security
women with effective contraception during the treatment and for 6 months after stopping

Exclusion Criteria

General criteria
Pregnant women, breastfeeding
Hypersensitivity to the active substance or any of its excipients
Hypersensitivity to the products of Chinese hamster ovary cells or other human or humanized recombinant antibodies
Inability to undergo medical monitoring due to reasons geographical, social or psychological
Patient under guardianship
Patient included in another biomedical research protocol
Related to medical history criteria
Uncontrolled hypertension ( systolic BP > or = 150 mmHg and / or Diastolic BP > or = 100 mmHg)
Thrombocytopenia <100 G / L
Taking NSAIDs within ten days prior to inclusion
Anticoagulant therapy or thrombolytic within 28 days before inclusion
Tumor, genetic predisposition to bleeding, coagulopathy , patient receiving treatment full anticoagulant dose for an event thromboembolism prior to inclusion
Major surgery within 28 days prior to inclusion
History of thromboembolic disease within 6 months prior to enrollment
Arteriovenous malformation localized to the brain, liver or lung on scanner older than 5 years
History of heart failure
Patients with proteinuria / creatinine greater than 2g / g
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note